(AGENPARL) - Roma, 29 Settembre 2023 - (AGENPARL) – ven 29 settembre 2023 No images? Click here https://worldhealthorganization.cmail19.com/t/d-e-vithrll-iitylyihjr-k/
Friday, 29 September 2023
News Release
Recommendations announced for
influenza vaccine composition for the 2024 southern hemisphere influenza season [https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season]
The World Health Organization (WHO) today announced the recommendations for the viral composition of influenza vaccines for the 2024 influenza season in the southern hemisphere [https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season]. The announcement was made at an information session at the end of a 4-day meeting on the Composition of Influenza Virus Vaccines, a meeting that is held twice annually.
WHO organizes these consultations with an advisory group of experts gathered from WHO Collaborating Centres and WHO Essential Regulatory Laboratories to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season.
The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including those circulating and infecting humans.
The WHO recommends that trivalent vaccines for use in the 2024 southern hemisphere influenza season contain the following:
Egg-based vaccines
Cell culture- or recombinant-based vaccines
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2024 southern hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Related links:
Frequently Asked Questions – Recommended composition of influenza virus vaccines [https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2024/202309_qanda_recommendation.pdf?sfvrsn=7a6906d1_5] Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness in the 2024 southern hemisphere influenza season [https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2024/202309_zoonotic_vaccinvirusupdate.pdf?sfvrsn=e78676a0_5] Seasonal candidate vaccine viruses and potency testing reagents for development and production of vaccines [https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses] Zoonotic candidate vaccine viruses and potency testing reagents for development and production of vaccines [https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses]
POST VPC AUDIO FILE
Please find below link to the audio files from the Virtual Press Conference held today, Friday 29 September, at 13:30hrs/1:30pm local time, at WHO headquarters in Geneva.
Press conference:
[https://who.canto.global/b/KPP0T]
Speakers were:
Dr Sylvie BRIAND, Director, WHO Director, Epidemic and Pandemic Preparedness and PreventionDr Wenqing ZHANG, Head, WHO Global Influenza Programme (GIP)Dr Kanta SUBBARAO, Director, WHO Collaborating Centre for Reference and Research on Influenza, Victoria Infectious Diseases Reference Laboratory (VIDRL), AustraliaDr Richard WEBBY, Director, WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, USADr David WENTWORTH, Director, WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention (CDC), USA
Media contact: